Vanguard Capital Management’s Xenetic Biosciences XBIO Stock Holding History

Vanguard Capital Management’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.9K	Buy	12,681 +5,950	+88%	+$18.4K	﹤0.01%	3964
2026 Q1	$18K	Buy	+6,731	New	+$16.6K	﹤0.01%	3990

Other funds holding XBIO

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DWM

Darwin Wealth Management Tampa, Florida $365M AUM 22.69% 1-Year Est. Return

Vanguard Capital Management's XBIO Position: Q2 2026 in Review

Vanguard Capital Management increased its Xenetic Biosciences (XBIO) stake by 88% in Q2 2026, buying an estimated $18.4K and bringing the position to 12,681 shares worth $36.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3964.

Vanguard Capital Management first reported a position in XBIO in Q1 2026 and has held it in 2 quarters since. 8 funds tracked by Wall St. Rank hold XBIO as of Q2 2026.

Vanguard Capital Management held 12,681 shares of Xenetic Biosciences worth $36.9K as of Q2 2026.
Vanguard Capital Management bought 5,950 Xenetic Biosciences shares in Q2 2026, an estimated $18.4K.
Xenetic Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3964 holding.
Vanguard Capital Management first reported a position in Xenetic Biosciences in Q1 2026 and has held it in 2 quarters since.
8 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.